These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer. Debruyne FM. Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760 [Abstract] [Full Text] [Related]
6. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results. Borgmann V, al-Abadi H, Nagel R. Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759 [Abstract] [Full Text] [Related]
8. Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial. Ostri P, Bonnesen T, Nilsson T, Frimodt-Møller C. Urol Int; 1991; 46(2):167-71. PubMed ID: 1711250 [Abstract] [Full Text] [Related]
9. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases]. Tauveron I, Hermabessière J. Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277 [No Abstract] [Full Text] [Related]
12. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M, Collette L, Members of the EORTC Genito-Urinary Group. Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109 [Abstract] [Full Text] [Related]
13. [Cyproterone acetate (Androcur-depo) in the treatment of inoperable prostatic cancer]. Stepanov VN, Goriunov VG, Chechenin MG, Sivkov AV, Gubdurakhmanov II. Urol Nefrol (Mosk); 1995 Apr; (6):33-6. PubMed ID: 8686122 [Abstract] [Full Text] [Related]
14. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group. Pavone-Macaluso M, Schröder FH, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R, Smith PH, Suciu S. Prog Clin Biol Res; 1989 Apr; 303():111-6. PubMed ID: 2528735 [No Abstract] [Full Text] [Related]
15. [Chemotherapy of advanced prostate cancer]. Hofmann W, Langkopf B. Z Urol Nephrol; 1986 Jan; 79(1):33-9. PubMed ID: 2938361 [No Abstract] [Full Text] [Related]
16. Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database. Seaman HE, Langley SE, Farmer RD, de Vries CS. BJU Int; 2007 Jun; 99(6):1398-403. PubMed ID: 17537215 [Abstract] [Full Text] [Related]
17. [Serum prolactin levels during therapy of prostatic cancer with oestradiol-17 beta-undecylate and cyproterone acetate (author's transl)]. Spona J, Lunglmayr G. Wien Klin Wochenschr; 1980 Jul 04; 92(14):494-7. PubMed ID: 6933738 [Abstract] [Full Text] [Related]
18. [Prostate cancer]. Kawai T, Washizuka M, Takahashi T, Kusuyama H. Gan To Kagaku Ryoho; 1984 May 04; 11(5):999-1004. PubMed ID: 6202247 [Abstract] [Full Text] [Related]
19. [Treatment of prostatic cancer]. J Urol (Paris); 1984 May 04; 90(10):619-48. PubMed ID: 6242517 [No Abstract] [Full Text] [Related]
20. [Prostatic cancer before the age of 50--report of 7 cases]. Aubert J, Dore B, Irani J, Aubert MN. Prog Urol; 1991 Jun 04; 1(3):432-9. PubMed ID: 1726944 [Abstract] [Full Text] [Related] Page: [Next] [New Search]